Skip to main content

CorMedix Inc 8-K, filed Nov 2, 2026

CorMedix Inc. (CRMD)

8-K 2026-11-02 For: 2026-11-02
View Original
Added on November 02, 2026

About this 8-K

CorMedix Inc filed this 8-K on November 2, 2026.

CorMedix Therapeutics reported approximately $355 million in unaudited cash and cash equivalents as of September 30, 2026 and reaffirmed full-year 2026 total revenue guidance of $325 million to $345 million. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits